The Fonds de solidarité FTQ is investing $10 million in Inversago, a Québec biotech firm focused on the development of treatments for rare diseases such as Prader-Willi Syndrome and metabolic disorders such as non-alcoholic steatohepatitis (NASH) and type 1 diabetes.
Read MoreInnomar Strategies, Canada's leading specialty pharmaceuticals service provider and a part of AmerisourceBergen, announced today it is the first and only service provider in Canada to have all of its clinics and home care nursing services achieve certification by Intertek under the ISO 9001:2015 standard from the International Organization for Standardization (ISO), effective January 30, 2020. This accomplishment reflects Innomar's ongoing commitment and investment in quality management systems to advance efficiency, increase customer satisfaction and enhance patient safety.
Read MoreNovartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that PIQRAY® (alpelisib) is approved and now available in Canada. PIQRAY® in combination with fulvestrant is indicated for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.10 This approval marks the first-ever treatment specifically for HR-positive, HER2-negative metastatic breast cancer with a PIK3CA mutation and is based on results from the pivotal SOLAR-1 clinical trial, which included ten Canadian trial sites and ten Canadian investigators.
Read MoreVantage BioTrials, a full service Contract Research Organization (CRO), has partnered with its biotech Sponsor, Laurent Pharmaceuticals, to lead all clinical trial management activities of their lead oral drug candidate LAU-7b in a multicentric Phase 2 placebo-controlled clinical trial (RESOLUTION) in patients with COVID-19.
Read MoreLaurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has received approval from the Food and Drug Administration (FDA) to start enrolling U.S. patients in RESOLUTION, a multicentric Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential treatment against COVID-19 disease. RESOLUTION, which is currently ongoing in Canada, will enroll approximately 200 hospitalized COVID-19 patients who will receive either LAU-7B or a placebo for a treatment duration of 14 days. The company is in advanced discussions with a number of U.S. hospitals interested to participate in the trial and is looking to activate them very soon.
Read MoreIRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, announces a new investment in ExCellThera Inc., a clinical-stage cell and molecular medicine company which it co-founded in 2015.
Read MoreIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.
Read MoreMcGill University and CQDM announced today that a collaborative project between McGill and nplex biosciences to further develop a highly-scalable protein detection method, termed the “nELISA”, has been selected for funding by CQDM.
Read MoreThe pandemic has highlighted the importance of supporting scientific research in order to allow investigators to find real solutions to deal with public health issues such as COVID-19 or cancer.
Read MoreIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, provides further details today on the Company’s rapid progress in developing its candidate vaccine to prevent COVID-19 infection in response to the global health threat posed by the novel coronavirus.
Read MoreToday BML Technology is proud to announce the launch of the COVID-19 Digital Health Task Force, in collaboration with elite partners and collaborators from the core of the Montreal health tech ecosystem, including the CNRC, McGill University, le CHUM, Fasken Martineau DuMoulin, Montreal InVivo, and Avisio Qualité, as well as institutions with international reach, like Montréal International and Medteq+.
Read MoreThe CQDM is launching its new SynergiQc program, designed to stimulate industrial research in the biopharmaceutical field within academic settings and to create economic benefits for Quebec.
Read MoreCAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, today announced it has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb (BMS) (NYSE:BMY).
Read MoreIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive preclinical results demonstrating robust immunogenic and antibody responses from the majority of peptide epitopes.
Read MoreAlethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial to mesenchymal transition (EMT).
Read MoreToronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.
Read MoreDIEX Recherche is proud to announce the opening of its fourth research center in Quebec. CEO Suzie Talbot made the announcement at DIEX Recherche in Sherbrooke. She insists that it is important to have good news to share these days. The opening of a new center will provide the local population of this beautiful region with innovative clinical trials.
Read MoreNew information on COVID-19 emerges every day. Researchers and scientists in Canada and around the world are working hard to better understand the virus, and its impacts on people and communities. By keeping pace with this information, we can better protect the health of Canadians and set our country on the path to recovery.
Read More
